- Home
- CTOR vs BEAT Comparison
CTOR vs BEAT Comparison
Compare CTOR & BEAT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CTOR
- BEAT
- Stock Information
- Founded
- CTOR 2021
- BEAT 2015
- Country
- CTOR United States
- BEAT United States
- Employees
- CTOR N/A
- BEAT N/A
- Industry
- CTOR
- BEAT Retail: Computer Software & Peripheral Equipment
- Sector
- CTOR
- BEAT Technology
- Exchange
- CTOR NYSE
- BEAT Nasdaq
- Market Cap
- CTOR 52.2M
- BEAT 59.0M
- IPO Year
- CTOR N/A
- BEAT 2021
- Fundamental
- Price
- CTOR $0.87
- BEAT $1.77
- Analyst Decision
- CTOR Strong Buy
- BEAT Buy
- Analyst Count
- CTOR 2
- BEAT 1
- Target Price
- CTOR $4.50
- BEAT $8.00
- AVG Volume (30 Days)
- CTOR 65.0K
- BEAT 53.6K
- Earning Date
- CTOR 05-21-2025
- BEAT 05-13-2025
- Dividend Yield
- CTOR N/A
- BEAT N/A
- EPS Growth
- CTOR N/A
- BEAT N/A
- EPS
- CTOR N/A
- BEAT N/A
- Revenue
- CTOR N/A
- BEAT N/A
- Revenue This Year
- CTOR N/A
- BEAT N/A
- Revenue Next Year
- CTOR N/A
- BEAT N/A
- P/E Ratio
- CTOR N/A
- BEAT N/A
- Revenue Growth
- CTOR N/A
- BEAT N/A
- 52 Week Low
- CTOR $0.55
- BEAT $1.45
- 52 Week High
- CTOR $49.00
- BEAT $3.48
- Technical
- Relative Strength Index (RSI)
- CTOR N/A
- BEAT 47.28
- Support Level
- CTOR N/A
- BEAT $1.78
- Resistance Level
- CTOR N/A
- BEAT $1.91
- Average True Range (ATR)
- CTOR 0.00
- BEAT 0.14
- MACD
- CTOR 0.00
- BEAT 0.02
- Stochastic Oscillator
- CTOR 0.00
- BEAT 38.01
About CTOR CITIUS ONCOLOGY INC
Citius Oncology Inc is a specialty pharmaceutical company dedicated to the development and commercialization of critical care products targeting unmet needs with a focus on oncology products. In addition, Citius completed enrollment in its Phase 2b trial of CITI-002 (Halo-Lido), a topical formulation for the relief of hemorrhoids.
About BEAT Heartbeam Inc.
HeartBeam Inc is a medical technology company primarily focusing on developing and commercializing higher resolution ambulatory Electrocardiogram ("ECG") solutions that enable the detection and monitoring of cardiac disease outside a healthcare facility setting. The Company's ability to develop higher-resolution ECG solutions is achieved through the development of the Company's proprietary and patented Vector Electrocardiography ("VECG") technology platform. The Company has validated this technology and is seeking U.S. Food and Drug Administration ("FDA") clearance for its initial telehealth products.